The evolution of thalidomide and its IMiD derivatives as anticancer agents
Top Cited Papers
- 1 April 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (4) , 314-322
- https://doi.org/10.1038/nrc1323
Abstract
No abstract availableThis publication has 53 references indexed in Scilit:
- The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myelomaLeukemia, 2004
- Thalidomide Inhibits Tumor Necrosis Factor-α Production and Antigen Presentation by Langerhans CellsJournal of Investigative Dermatology, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Thalidomide as an anti‐cancer agentJournal of Cellular and Molecular Medicine, 2002
- Effect of Thalidomide on Chemokine Production by Human MicrogliaThe Journal of Infectious Diseases, 2000
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide in Crohn's diseaseThe Lancet, 1997
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Treatment of Behçet's disease with thalidomideClinical Rheumatology, 1986